Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- S-4 Registration of securities issued in business combination transactions
- 10.34 EX-10.34
- 10.35 EX-10.35
- 10.36 EX-10.36
- 10.37 EX-10.37
- 10.38 EX-10.38
- 10.39 EX-10.39
- 10.40 EX-10.40
- 10.41 EX-10.41
- 10.42 EX-10.42
- 10.43 EX-10.43
- 10.44 EX-10.44
- 10.45 EX-10.45
- 10.46 EX-10.46
- 10.47 EX-10.47
- 10.48 EX-10.48
- 21.1 EX-21.1
- 23.1 EX-23.1
- 23.5 EX-23.5
- 99.5 EX-99.5
- 99.6 EX-99.6
- 99.7 EX-99.7
- 99.8 EX-99.8
- 99.9 EX-99.9
- Download Excel data file
- View Excel data file
NRBO similar filings
- 4 Nov 19 Registration of securities issued in business combination transactions (amended)
- 30 Oct 19 Registration of securities issued in business combination transactions (amended)
- 10 Oct 19 Registration of securities issued in business combination transactions (amended)
- 3 Sep 19 Registration of securities issued in business combination transactions
Filing view
External links
August 30, 2019
Gemphire Therapeutics Inc.
P.O. Box 130235
Ann Arbor, MI 48113
Consent to Reference in Proxy Statement/Prospectus/Information Statement
Gemphire Therapeutics Inc. (the “Company”) has filed a Registration Statement on Form S-4 (Registration No. 333- ) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”). In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to the reference to me in the proxy statement/prospectus/information statement included in such registration statement as a future member of the board of directors of the Company.
Sincerely, | |
|
|
/s/ Jeong Gyun Oh | |
Name: Jeong Gyun Oh |